Advertisement

Targeting Signaling Pathways – In the Search of Melanoma’s Achilles’ Heel

  • Nikolas K. Haass
  • Christoph Hoeller
  • Meenhard Herlyn
Part of the TTME book series (TTME, volume 2)

Abstract

Melanoma is the most aggressive form of skin cancer and is highly resistant to conventional chemotherapy, immunotherapy and targeted therapy. The prognosis for metastatic melanoma remains dismal with average survival rates of 6–10 months. Dacarbazine with response rates of less than 10% and a median progression free survival of 2 months is currently the only standard agent. Despite promising results with combination chemotherapy in vitro, and better response rates in patients, no randomized clinical trial has shown a survival advantage over single agent dacarbazine. Thus, new therapeutic targets are urgently needed to improve the dismal prognosis of this disease. The mitogen activated protein kinase (MAPK) pathway is constitutively active in most melanomas. The finding that over 60% of melanomas harbor the activating BRAFV600E mutation has raised expectations for the targeted therapy of melanoma. Small molecule signalling pathway inhibitors are now available for BRAF, BRAFV600E, NRAS, MEK, mTOR, VEGF and others. In this review we discuss the role of targeting various constituents of the MAPK pathway and of mammalian target of rapamycin (mTOR). Finally we discuss the alternative approach of targeting melanoma stem cells as a putative therapy.

Keywords

Targeted therapy MAPKinase BRAF Activating mutation c-KIT MEK PI3K mTOR Melanoma stem cells Multidrug resistance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Clark WH, Jr., Elder DE, Guerry Dt, Epstein MN, Greene MH, Van Horn M (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15:1147–1165PubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRefGoogle Scholar
  3. 3.
    Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622–3634PubMedGoogle Scholar
  4. 4.
    Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687–701PubMedGoogle Scholar
  5. 5.
    Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM (2006) Isolated limb perfusion for melanoma patients – a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol 32:371–380CrossRefPubMedGoogle Scholar
  6. 6.
    Serrone L, Zeuli M, Sega FM, Cognetti F (2000) Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19:21–34PubMedGoogle Scholar
  7. 7.
    Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748–759CrossRefPubMedGoogle Scholar
  8. 8.
    Atkins MB (2006) Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12:2353s–2358sCrossRefPubMedGoogle Scholar
  9. 9.
    Jack A, Boyes C, Aydin N, Alam K, Wallack M (2006) The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surg Oncol 15:13–24CrossRefPubMedGoogle Scholar
  10. 10.
    Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738–4745CrossRefPubMedGoogle Scholar
  11. 11.
    Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9:180–186CrossRefPubMedGoogle Scholar
  12. 12.
    Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE (2005) Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 24:3459–3471CrossRefPubMedGoogle Scholar
  13. 13.
    Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63:756–759PubMedGoogle Scholar
  14. 14.
    Brazil DP, Park J, Hemmings BA (2002) PKB binding proteins. Getting in on the Akt. Cell 111:293–303Google Scholar
  15. 15.
    Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M (2006) Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 66:4182–4190CrossRefPubMedGoogle Scholar
  16. 16.
    Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340–4346CrossRefPubMedGoogle Scholar
  17. 17.
    Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997–7000PubMedGoogle Scholar
  18. 18.
    Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMedGoogle Scholar
  19. 19.
    Smalley KSM (2003) A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104:527–532CrossRefPubMedGoogle Scholar
  20. 20.
    Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358–362CrossRefPubMedGoogle Scholar
  21. 21.
    Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313–319CrossRefPubMedGoogle Scholar
  22. 22.
    Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867CrossRefPubMedGoogle Scholar
  23. 23.
    Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23:6292–6298CrossRefPubMedGoogle Scholar
  24. 24.
    Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198–5202PubMedGoogle Scholar
  25. 25.
    Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S (2006) Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66:999–1006CrossRefPubMedGoogle Scholar
  26. 26.
    Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835–844CrossRefPubMedGoogle Scholar
  27. 27.
    Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O’Dwyer PJ, Ratain MJ (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95:581–586CrossRefPubMedGoogle Scholar
  28. 28.
    Amaravadi RK, Schuchter LM, Kramer A (2006) Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol 24 (18S):8009Google Scholar
  29. 29.
    Flaherty KT, Brose M, Schuchter LM (2004) Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 22 (14S):7507Google Scholar
  30. 30.
    Flaherty KT, Redlinger M, Schuchter LM, Lathia CD, Weber BL, O’Dwyer PJ (2005) Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. Proc Am Soc Clin Oncol:3037Google Scholar
  31. 31.
    Amiri P, Aikawa ME, Dove J, Stuart DD, Poon D, Pick T, Ramurthy S, Subramanian S, Levine B, Costales A, Harris A, Paul R (2006) CHIR-265 is a potent selective inhibitor of c-RAF/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations. Proc Am Assoc Cancer Res:4855Google Scholar
  32. 32.
    King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, Tuveson DA, Huang PS (2006) Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 66:11100–11105CrossRefPubMedGoogle Scholar
  33. 33.
    Tsai J, Zhang J, Bremer R, Artis R, Hirth P, Bollag G (2006) Development of a Novel Inhibitor of Oncogenic B-Raf. Proc Am Assoc Cancer Res:2412Google Scholar
  34. 34.
    Lee JT, Haass NK, Kong J, Sproesser K, Tsai J, Cho H, Li L, Smalley KSM, Bollag G, Herlyn M (2006) Antitumor Activity of PLX4032, a Novel B-Raf V600E Inhibitor. EORTC-NCI-AACR 2006Google Scholar
  35. 35.
    Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281–5293CrossRefPubMedGoogle Scholar
  36. 36.
    Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456–4462CrossRefPubMedGoogle Scholar
  37. 37.
    Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS (2008) The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14:230–239CrossRefPubMedGoogle Scholar
  38. 38.
    Smalley KS, Herlyn M (2005) Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann NY Acad Sci 1059:16–25CrossRefPubMedGoogle Scholar
  39. 39.
    Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002–7010CrossRefPubMedGoogle Scholar
  40. 40.
    Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499–3511CrossRefPubMedGoogle Scholar
  41. 41.
    Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR (2000) Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14:2501–2514CrossRefPubMedGoogle Scholar
  42. 42.
    Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM (2003) GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11:895–904CrossRefPubMedGoogle Scholar
  43. 43.
    Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296–1302CrossRefPubMedGoogle Scholar
  44. 44.
    Corradetti MN, Guan KL (2006) Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 25:6347–6360CrossRefPubMedGoogle Scholar
  45. 45.
    Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619CrossRefPubMedGoogle Scholar
  46. 46.
    Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 15:6541–6551PubMedGoogle Scholar
  47. 47.
    Hresko RC, Mueckler M (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280:40406–40416CrossRefPubMedGoogle Scholar
  48. 48.
    Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101CrossRefPubMedGoogle Scholar
  49. 49.
    Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159–168CrossRefPubMedGoogle Scholar
  50. 50.
    Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, Lichtenstein A (2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104:4181–4187CrossRefPubMedGoogle Scholar
  51. 51.
    Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ (2001) Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61:1527–1532PubMedGoogle Scholar
  52. 52.
    Gallicchio MA, van Sinderen M, Bach LA (2003) Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth. Horm Metab Res 35:822–827CrossRefPubMedGoogle Scholar
  53. 53.
    Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH (2005) CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104:1045–1048CrossRefPubMedGoogle Scholar
  54. 54.
    Bedogni B, Welford SM, Kwan AC, Ranger-Moore J, Saboda K, Powell MB (2006) Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 5:3071–3077CrossRefPubMedGoogle Scholar
  55. 55.
    Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136–1144CrossRefPubMedGoogle Scholar
  56. 56.
    Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., Abraham RT (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. Embo J 15:5256–5267PubMedGoogle Scholar
  57. 57.
    Toral-Barza L, Zhang WG, Lamison C, Larocque J, Gibbons J, Yu K (2005) Characterization of the cloned full-length and a truncated human target of rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay. Biochem Biophys Res Commun 332:304–310CrossRefPubMedGoogle Scholar
  58. 58.
    Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179–183CrossRefPubMedGoogle Scholar
  59. 59.
    Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9:341–349CrossRefPubMedGoogle Scholar
  60. 60.
    Werzowa J, Pratscher B, Cejka D, Pehamberger H, Wacheck V (2006) mTORC1 inhibition with rapamycin leads to activation of PI3K/AKT signalling via an mTORC2 dependent mechanism in melanoma cells. EORTC-NCI-AACR 2006Google Scholar
  61. 61.
    Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137:231–245CrossRefPubMedGoogle Scholar
  62. 62.
    Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D, Hauschild A (2006) Molecularly targeted therapy for melanoma: current reality and future options. Cancer 107:2317–2327CrossRefPubMedGoogle Scholar
  63. 63.
    Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111CrossRefPubMedGoogle Scholar
  64. 64.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988CrossRefPubMedGoogle Scholar
  65. 65.
    Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737CrossRefPubMedGoogle Scholar
  66. 66.
    Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648CrossRefPubMedGoogle Scholar
  67. 67.
    Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMedGoogle Scholar
  68. 68.
    Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401CrossRefPubMedGoogle Scholar
  69. 69.
    Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328–9337CrossRefPubMedGoogle Scholar
  70. 70.
    Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284CrossRefPubMedGoogle Scholar
  71. 71.
    Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58CrossRefPubMedGoogle Scholar
  72. 72.
    Gros P, Ben Neriah YB, Croop JM, Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728–731CrossRefPubMedGoogle Scholar
  73. 73.
    Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V (1985) Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316:817–819CrossRefPubMedGoogle Scholar
  74. 74.
    Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83:4538–4542CrossRefPubMedGoogle Scholar
  75. 75.
    Ueda K, Cornwell MM, Gottesman MM, Pastan I, Roninson IB, Ling V, Riordan JR (1986) The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 141:956–962CrossRefPubMedGoogle Scholar
  76. 76.
    Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468–7485CrossRefPubMedGoogle Scholar
  77. 77.
    Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320–4333CrossRefPubMedGoogle Scholar
  78. 78.
    Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, Sayegh MH, Frank MH (2003) Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 278:47156–47165CrossRefPubMedGoogle Scholar
  79. 79.
    Deichmann M, Thome M, Egner U, Hartschuh W, Kurzen H (2005) The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin. J Cutan Pathol 32:467–473CrossRefPubMedGoogle Scholar
  80. 80.
    Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, et al. (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124CrossRefPubMedGoogle Scholar
  81. 81.
    Depeille P, Cuq P, Passagne I, Evrard A, Vian L (2005) Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer 93:216–223CrossRefPubMedGoogle Scholar
  82. 82.
    Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM (1995) Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 147:1545–1552PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Nikolas K. Haass
    • 1
    • 2
  • Christoph Hoeller
  • Meenhard Herlyn
  1. 1.The Wistar InstitutePhiladelphiaUSA
  2. 2.Centenary Institute of Cancer Medicine and Cell Biology, Royal Prince Alfred Hospital, University of SydneyNewtownAustralia

Personalised recommendations